Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Calendar
  • Grants
  • About Akademiliv
Bild från bildbyrån iStock.

Researchers identify a new biomarker for the childhood cancer neuroblastoma

15 January, 2021 Leave a Comment

NEW STUDY. In collaboration with researchers in the Netherlands and Belgium, researchers at the University of Gothenburg have now shown that overexpression of the gene for ALKAL2 activates a chain of other cancer-driving genes and how this leads to neuroblastoma. The results indicate that increased gene dosage of ALKAL2 may become a new biomarker and open up the potential for treatment with ALK inhibitors for certain forms of childhood cancer.

Neuroblastoma is a heterogeneous cancer. The disease mainly affects young children and is found in both mild and very aggressive forms. Despite improvements in treatments, long-term survival is still low for children with aggressive neuroblastoma. Neuroblastoma occurs in the sympathetic nervous system, which is part of the involuntary nervous system, and can cause tumors in various locations in the body.

Chromosome-level defects

The mechanisms that initiate cancer development in neuroblastoma are largely unknown, but a few cancer-driving genes have been identified. Examples of such oncogenes in neuroblastoma are the receptor for ALK tyrosine kinase and the gene MYCN, when overexpressed.

Marcus Borenäs. (Private photo).

“The genetic defects considered a primary cause in the development of neuroblastoma are found at the chromosome level. Parts of chromosomes can be missing and several different chromosomes can be overexpressed at the same time or each separately,” says Marcus Borenäs, a doctoral student at the University of Gothenburg and researching intern physician at Sahlgrenska University Hospital, who is a shared co-first author of the new study.

Disturbed gene dosage

Patients with a poor prognosis from high-risk neuroblastoma have genetic defects, such as deletion of certain parts from chromosome arms 1p and 11q, more copies of parts from chromosomes 2p and 17q, or overexpression of oncogenic MYCN. Gene expression is thought to be affected when they receive more or fewer copies, which may contribute to the development of neuroblastoma.

“Understanding these underlying molecular mechanisms and placing them in a developmental context is important for understanding how neuroblastoma occurs and how it survives despite aggressive treatment regimens,” said Ruth Palmer, a professor at the Institute of Biomedicine and the last author of the study.

ALKAL2 activated unmutated receptors

Together with colleagues, Ruth Palmer has investigated the function of the protein ALKAL2 since 2015, when the group managed to identify it as a ligand that activates the receptor for the ALK gene. In mutated form, the ALK receptor is a described oncogene in neuroblastoma, but the study shows that the receptor can also contribute to neuroblastoma development in unmutated form.

The study shows that an increased expression of ALKAL2 can activate ALK even if the receptor has no mutation. This leads to growth in cell cultures and to tumor development in a mouse model with a high expression of MYCN.

Chain reaction in the cell nucleus

The effect is that the ALK receptor is activated by the ligand ALKAL2, this enzymatic activity reverses the transcription in the cell nucleus, and many new genes are turned on or off. One of the genes that is turned on is the known oncogene MYCN.

Ruth Palmer. Photo: Johan Wingborg.

“Interestingly, these genes are located close to each other on chromosome 2. We know that ALKAL2 is at position 2p25, near the end of chromosome 2p. ALK and MYCN are also located on chromosome 2, relatively close, more specifically at positions 2p23 and 2p24, respectively,” says Ruth Palmer.

Together with the geneticist Tommy Martinsson, also a professor at the Institute of Biomedicine, the group has previously reported that about 30 percent of all neuroblastomas have amplification or some overexpression of this part on chromosome 2. There are also reports that there is a link between patients with more copies of chromosome 2 and poorer disease prognosis, and, as such, lower survival.

Possible new treatment

“We know about the major mechanistic events caused by 2p troika overexpression, resulting in illness. Now we have started digging deeper to understand when it happens, that is, at what stage we lose control of cell growth and cancer develops,” says Marcus Borenäs.

In light of this new information, the authors of the article conclude that increased expression of ALKAL2 should also be included as a future biomarker for neuroblastoma. This also opens up the opportunity for new beneficial treatments.

“If there is too much of the ligand ALKAL2 that activates ALK, this can be stopped with ALK inhibitors. Such drugs are already being used successfully today in the treatment of ALK-positive lung cancer. At present, it cannot be ruled out that tumors with overexpression of the 2p troika ALKAL2, ALK and MYCN could be treated with ALK inhibitors,” Ruth Palmer concludes.

The study has been recently published in the EMBO Journal.

Title: ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation; https://www.embopress.org/doi/full/10.15252/embj.2020105784

Authors: Marcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, Dan E Lind, Barbara Witek, Jikui Guan, Patricia Mendoza-Garcia, Tafheem Masudi, Arne Claeys, Tzu-Po Chuang, Abeer El Wakil, Badrul Arefin, Susanne Fransson, Jan Koster, Mathias Johansson, Jennie Gaarder, Jimmy Van den Eynden, Bengt Hallberg and Ruth H Palmer.

 

TEXT: ELIN LINDSTRÖM

By: Elin Lindström
Tagged With: Cancerforskning, institutionen för biomedicin

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Add your own events in the Akademiliv Calendar

Björn Burmann: Biological solution NMR – From structure and dynamics towards cell biology

  • Webinar 15:00-16:00, Thursday March 4.
  • Link to Zoom webinar.

Engineering Health, April 13-14.

Program and registration now available for Engineering Heath, held as a digital event April 13-14, 2021.

Forskarsnabben – full autumn program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life. Start January 27.
English version further down in the document.

The novel coronavirus – University-wide information on the Staff Portal

Read up-tp-date information regarding how effects of the pandemic are handled at the university.

The entrance doors are locked

Due to new restrictions and decisions, all entrances are locked. For daytime access, use your GU card.

We are building at Medicinareberget

You will now find comprehensive information on construction projects that affect the Sahlgrenska Academy in the Staff Portal.

Lunch menus

Café & restaurang Anatomen

Gastronomen på SU

Lunchen.nu

Lyktan lunchservering

Lustgården på Änggårdsbacken

Café Anne Dahl

More news

Socioeconomics and heart disease among people living near railways

25 February, 2021

GRANTS. Formas has awarded Natalia Caldeira Loss Vincens, a postdoc in occupational and environmental medicine, SEK 3 million in a project grant …  

They are the first doctoral students in medical engineering in collaboration with Chalmers

24 February, 2021

DOCTORAL STUDIES. So far, two doctoral students at Sahlgrenska Academy have begun their doctoral studies in medical engineering in collaboration …  

The large ALF grant round opens soon – get answers to your questions at the March 15 webinar

23 February, 2021

ALF GRANTS. You can submit your application for ALF grants until June 1. Sahlgrenska Academy and Sahlgrenska University Hospital are holding a …  

TBE patients’ lasting problems

23 February, 2021

DOCTORAL THESIS. Impaired memory, reduced motivation, and declining motor skills. These are some of the problems that may persist several years af …  

A fifth of adults in Sweden experience dental anxiety 

22 February, 2021

DOCTORAL THESIS. In Sweden, approximately one in five adults suffers from dental anxiety or phobia. The number has decreased over time, but many s …  

Meet language stylist Ola Bratt — new professor of clinical cancer epidemiology

19 February, 2021

PEOPLE. Ola Bratt is our new professor of clinical cancer epidemiology at the University of Gothenburg. Back in the early 1990s, as a newly …  

Researchers in engineering sciences and medicine learn from each other to develop future health care technology

19 February, 2021

RESEARCH SCHOOL. Research in the borderland between technology and health is becoming increasingly important. Now Chalmers University of …  

Hospital wastewater favors multi-resistant bacteria

17 February, 2021

NEW STUDY. Scientists from the University of Gothenburg, Sweden presents evidence that hospital wastewater, containing elevated levels of …  

Age important factor for new intestinal barrier component against bacteria

17 February, 2021

NEW SYUDY. How do intestinal cells perceive when to put up defenses against intruding bacteria? Which signals are required for a functional …  

Construction information Medicinareberget – Walls, ceilings and beams are beginning to come in place

15 February, 2021

CONSTRUCTION INFORMATION. Akademiliv provides information on the construction of Natrium on Medicinareberget for the period weeks 7-10 (February …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström Claessen is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen